Keywords: UK, NICE, Novartis, Gilenya, Multiple sclerosis, Roche, MabThera, Follicular lymphoma
UK NICE says Novartis MS drug Gilenya not cost effective, but backs extended use of Roche’s MabThera
Article | 01 December 2011
In further draft guidance published today (December 1), UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) says ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
